{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T16:45:00Z","timestamp":1761237900863,"version":"build-2065373602"},"reference-count":29,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2012,7,1]],"date-time":"2012-07-01T00:00:00Z","timestamp":1341100800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2012,7,1]],"date-time":"2012-07-01T00:00:00Z","timestamp":1341100800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Toxicology Letters"],"published-print":{"date-parts":[[2012,7]]},"DOI":"10.1016\/j.toxlet.2012.05.002","type":"journal-article","created":{"date-parts":[[2012,5,10]],"date-time":"2012-05-10T09:40:46Z","timestamp":1336642846000},"page":"83-89","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":24,"title":["Prodigiosin-induced cytotoxicity involves RAD51 down-regulation through the JNK and p38 MAPK pathways in human breast carcinoma cell lines"],"prefix":"10.1016","volume":"212","author":[{"given":"Chien-Hsing","family":"Lu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shin-Chang","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shu-Yi","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mu-Yun","family":"Pan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yun-Wei","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chun-Yi","family":"Hsu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu-Hong","family":"Wei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jo-Shu","family":"Chang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chia-Che","family":"Chang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.toxlet.2012.05.002_bib0005","doi-asserted-by":"crossref","first-page":"2312","DOI":"10.1158\/0008-5472.CAN-07-2395","article-title":"The cyclin-dependent kinase inhibitor flavopiridol potentiates the effects of topoisomerase I poisons by suppressing Rad51 expression in a p53-dependent manner","volume":"68","author":"Ambrosini","year":"2008","journal-title":"Cancer Research"},{"key":"10.1016\/j.toxlet.2012.05.002_bib0010","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1038\/sj.embor.7400587","article-title":"p53 modulates homologous recombination by transcriptional regulation of the RAD51 gene","volume":"7","author":"Arias-Lopez","year":"2006","journal-title":"EMBO Reports"},{"key":"10.1016\/j.toxlet.2012.05.002_bib0015","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1016\/j.jbiosc.2010.12.026","article-title":"Development of natural anti-tumor drugs by microorganisms","volume":"111","author":"Chang","year":"2011","journal-title":"Journal of Bioscience and Bioengineering"},{"key":"10.1016\/j.toxlet.2012.05.002_bib0020","doi-asserted-by":"crossref","first-page":"2658","DOI":"10.1016\/j.yexcr.2009.06.002","article-title":"Emodin enhances gefitinib-induced cytotoxicity via Rad51 downregulation and ERK1\/2 inactivation","volume":"315","author":"Chen","year":"2009","journal-title":"Experimental Cell Research"},{"key":"10.1016\/j.toxlet.2012.05.002_bib0025","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/j.bcp.2011.11.027","article-title":"Identification of dual mTORC1 and mTORC2 inhibitors in melanoma cells: prodigiosin vs. obatoclax","volume":"83","author":"Espona-Fiedler","year":"2012","journal-title":"Biochemical Pharmacology"},{"key":"10.1016\/j.toxlet.2012.05.002_bib0030","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1054\/drup.2001.0214","article-title":"Role of mitogen-activated protein kinases in the response of tumor cells to chemotherapy","volume":"5","author":"Fan","year":"2001","journal-title":"Drug Resistance Updates"},{"key":"10.1016\/j.toxlet.2012.05.002_bib0035","doi-asserted-by":"crossref","first-page":"2893","DOI":"10.1002\/ijc.25516","article-title":"Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008","volume":"127","author":"Ferlay","year":"2008","journal-title":"International Journal of Cancer"},{"key":"10.1016\/j.toxlet.2012.05.002_bib0040","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/j.taap.2007.08.007","article-title":"Undecylprodigiosin selectively induces apoptosis in human breast carcinoma cells independent of p53","volume":"225","author":"Ho","year":"2007","journal-title":"Toxicology and Applied Pharmacology"},{"key":"10.1016\/j.toxlet.2012.05.002_bib0045","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.taap.2008.12.009","article-title":"Prodigiosin down-regulates survivin to facilitate paclitaxel sensitization in human breast carcinoma cell lines","volume":"235","author":"Ho","year":"2009","journal-title":"Toxicology and Applied Pharmacology"},{"key":"10.1016\/j.toxlet.2012.05.002_bib0050","doi-asserted-by":"crossref","DOI":"10.1111\/j.1476-5381.2012.01921.x","article-title":"Prodigiosin down-regulates SKP2 to induce p27KIP1 stabilization and antiproliferation in human lung adenocarcinoma cells","author":"Hsieh","year":"2012","journal-title":"British Journal of Pharmacology"},{"key":"10.1016\/j.toxlet.2012.05.002_bib0055","first-page":"69","article-title":"Global cancer statistics","volume":"61","author":"Jemal","year":"2011","journal-title":"CA: A Cancer Journal for Clinicians"},{"key":"10.1016\/j.toxlet.2012.05.002_bib0060","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1016\/j.dnarep.2007.12.008","article-title":"The consequence of Rad51 overexpression for normal and tumor cells","volume":"7","author":"Klein","year":"2010","journal-title":"DNA Repair (Amsterdam)"},{"key":"10.1016\/j.toxlet.2012.05.002_bib0065","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1093\/carcin\/bgn130","article-title":"Involvement of Rad51 in cytotoxicity induced by epidermal growth factor receptor inhibitor (gefitinib, IressaR) and chemotherapeutic agents in human lung cancer cells","volume":"29","author":"Ko","year":"2008","journal-title":"Carcinogenesis"},{"key":"10.1016\/j.toxlet.2012.05.002_bib0070","doi-asserted-by":"crossref","first-page":"3632","DOI":"10.1158\/1535-7163.MCT-08-0578","article-title":"Role of repair protein Rad51 in regulating the response to gefitinib in human non-small cell lung cancer cells","volume":"7","author":"Ko","year":"2008","journal-title":"Molecular Cancer Therapeutics"},{"key":"10.1016\/j.toxlet.2012.05.002_bib0075","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1016\/j.bcp.2009.09.024","article-title":"Suppression of ERCC1 and Rad51 expression through ERK1\/2 inactivation is essential in emodin-mediated cytotoxicity in human non-small cell lung cancer cells","volume":"79","author":"Ko","year":"2010","journal-title":"Biochemical Pharmacology"},{"key":"10.1016\/j.toxlet.2012.05.002_bib0080","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.taap.2011.07.012","article-title":"Curcumin enhances the mitomycin C-induced cytotoxicity via downregulation of MKK1\/2-ERK1\/2-mediated Rad51 expression in non-small cell lung cancer cells","volume":"255","author":"Ko","year":"2011","journal-title":"Toxicology and Applied Pharmacology"},{"key":"10.1016\/j.toxlet.2012.05.002_bib0085","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1093\/toxsci\/kfi149","article-title":"DNA interaction and dual topoisomerase I and II inhibition properties of the anti-tumor drug prodigiosin","volume":"85","author":"Montaner","year":"2005","journal-title":"Toxicological Sciences"},{"key":"10.1016\/j.toxlet.2012.05.002_bib0090","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/S0378-4274(01)00477-5","article-title":"The cytotoxic prodigiosin induces phosphorylation of p38-MAPK but not of SAPK\/JNK","volume":"129","author":"Montaner","year":"2002","journal-title":"Toxicology Letters"},{"key":"10.1016\/j.toxlet.2012.05.002_bib0095","unstructured":"NCCN clinical practice guidelines in oncology. Breast Cancer. 2nd ed., 2011. Available at: http:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/breast.pdf."},{"key":"10.1016\/j.toxlet.2012.05.002_bib0100","unstructured":"NCI, 2008. Available at: http:\/\/seer.cancer.gov\/statfacts\/html\/breast.html."},{"key":"10.1016\/j.toxlet.2012.05.002_bib0105","doi-asserted-by":"crossref","first-page":"732","DOI":"10.2174\/138161209787582192","article-title":"Prodigiosins as anti-cancer agents: living up to their name","volume":"15","author":"Pandey","year":"2009","journal-title":"Current Pharmaceutical Design"},{"key":"10.1016\/j.toxlet.2012.05.002_bib0110","doi-asserted-by":"crossref","first-page":"2222","DOI":"10.2174\/092986710791331103","article-title":"New insights on the antitumoral properties of prodiginines","volume":"17","author":"P\u00e9rez-Tom\u00e1s","year":"2010","journal-title":"Current Medicinal Chemistry"},{"key":"10.1016\/j.toxlet.2012.05.002_bib0115","doi-asserted-by":"crossref","first-page":"448","DOI":"10.2174\/187152008784220267","article-title":"Therapeutic exploitation of tumor cell defects in homologous recombination","volume":"8","author":"Powell","year":"2008","journal-title":"Anti-Cancer Agent Medical Chemistry"},{"key":"10.1016\/j.toxlet.2012.05.002_bib0120","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.canlet.2006.06.004","article-title":"Links between DNA double strand break repair and breast cancer. Accumulating evidence from both familial and nonfamilial cases","volume":"248","author":"Ralhan","year":"2007","journal-title":"Cancer Letters"},{"key":"10.1016\/j.toxlet.2012.05.002_bib0125","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1093\/nar\/gkp1063","article-title":"Overexpression of RAD51 suppresses recombination defects: a possible mechanism to reverse genomic instability","volume":"38","author":"Schild","year":"2010","journal-title":"Nucleic Acids Research"},{"key":"10.1016\/j.toxlet.2012.05.002_bib0130","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1158\/1535-7163.MCT-06-0266","article-title":"Prodigiosin induces the proapoptotic gene NAG-1 via glycogen synthase kinase-3beta activity in human breast cancer cells","volume":"6","author":"Soto-Cerrato","year":"2007","journal-title":"Molecular Cancer Therapeutics"},{"key":"10.1016\/j.toxlet.2012.05.002_bib0135","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1016\/j.bcp.2007.07.016","article-title":"The anticancer agent prodigiosin induces p21WAF1\/CIP1 expression via transforming growth factor-beta receptor pathway","volume":"4","author":"Soto-Cerrato","year":"2007","journal-title":"Biochemical Pharmacology"},{"key":"10.1016\/j.toxlet.2012.05.002_bib0140","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1124\/jpet.110.173146","article-title":"Down-regulation of Rad51 expression overcomes drug resistance to gemcitabine in human non-small-cell lung cancer cells","volume":"335","author":"Tsai","year":"2010","journal-title":"Journal of Pharmacology and Experimental Therapeutics"},{"key":"10.1016\/j.toxlet.2012.05.002_bib0145","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.ccr.2007.01.010","article-title":"Ten genes for inherited breast cancer","volume":"11","author":"Walsh","year":"2007","journal-title":"Cancer Cell"}],"container-title":["Toxicology Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0378427412011162?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0378427412011162?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T05:12:45Z","timestamp":1759900365000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0378427412011162"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,7]]},"references-count":29,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2012,7]]}},"alternative-id":["S0378427412011162"],"URL":"https:\/\/doi.org\/10.1016\/j.toxlet.2012.05.002","relation":{},"ISSN":["0378-4274"],"issn-type":[{"type":"print","value":"0378-4274"}],"subject":[],"published":{"date-parts":[[2012,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prodigiosin-induced cytotoxicity involves RAD51 down-regulation through the JNK and p38 MAPK pathways in human breast carcinoma cell lines","name":"articletitle","label":"Article Title"},{"value":"Toxicology Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.toxlet.2012.05.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2012 Elsevier Ireland Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}